Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 0.69 |
| ▸ | PDE3B | Q13370 | 11/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 11/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PDE2A | O00408 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353452 | 0.90 | SMN1; SMN2 (0.81) | SMN1; SMN2AXLPDE3BPDE3AKCNH2 | |
| SCHEMBL8800856 | 0.86 | SMN1; SMN2 (0.73) | SMN1; SMN2AXLPDE3BPDE3AGPR119 | |
| SCHEMBL11158097 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2AXLPDE3BPDE3AGPR119 | |
| SCHEMBL7263634 | 0.82 | KCNH2 (0.73) | SMN1; SMN2AXLPDE3BPDE3AKCNH2 | |
| SCHEMBL927560 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2PDE3BPDE3AKCNH2PDE2A | |
| SCHEMBL9687996 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2PDE3BPDE3AKCNH2PDE2A | |
| SCHEMBL2375581 | 0.82 | AXL (1.00) | SMN1; SMN2AXLPDE3BPDE3AGPR119 | |
| SCHEMBL6331085 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2PDE3BPDE3AKCNH2PDE2A | |
| SCHEMBL2846257 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2PDE3BPDE3AKCNH2PDE2A | |
| SCHEMBL8302890 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2PDE3BPDE3AKCNH2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8747643-B2 | Plating bath and method | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2014-06-10 | — | — | US | claimed |
| US-20140027298-A1 | PLATING BATH AND METHOD | ROHM & HAAS ELECT MAT (US) | 2014-01-30 | — | — | US | claimed |
| US-20130048505-A1 | PLATING BATH AND METHOD | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2013-02-28 | — | — | US | claimed |
| EP-0327800-B1 | 6-PHENYLDIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | HEUMANN PHARMA GMBH & CO (DE) | 1992-05-27 | — | — | EP | claimed |
| US-4954501-A | INOTROPIC AGENTS | HEUMANN PHARMA GMBH & CO. (DE) | 1990-09-04 | — | — | US | claimed |
| EP-0327800-A2 | 6-Phenyldihydro-3(2H)-pyridazinones, process for their preparation and medicines containing these compounds | HEUMANN PHARMA GMBH & CO (DE) | 1989-08-16 | — | — | EP | claimed |
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | claimed |
| US-4255571-A | Catalytic dehydrogenation preparation of 3-pyridazones | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-03-10 | — | — | US | claimed |
| US-20250115573-A1 | PYRIDAZINE-BASED PYRIDINE DERIVATIVES AS BIOLOGICALLY ACTIVE AGENTS | IMRAN MOHD (SA) | 2025-04-10 | — | — | US | disclosed |
| CN-115894324-B | Method for preparing pyrrolidone compound | 华北电力大学 | 2024-08-27 | — | — | CN | disclosed |
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-13 | — | — | US | disclosed |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-13 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-0042513-A1 | Dihydropyridazinones, processes for their preparation and pharmaceutical compositions containing these compounds | BASF Aktiengesellschaft (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4298609-A | 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents | STERLING DRUG INC. (US) | 1981-11-03 | — | — | US | disclosed |
| US-4293554-A | Method of treating asthma | AMERICAN CYANAMID COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| EP-0002719-B1 | PROCESS FOR THE PREPARATION OF 3-PYRIDAZINONES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-24 | — | — | EP | disclosed |
| US-4255571-A | Catalytic dehydrogenation preparation of 3-pyridazones | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-03-10 | — | — | US | disclosed |
| EP-0002719-A2 | Process for the preparation of 3-pyridazinones | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | SMN1; SMN2 1672/4885AXL 4760/4885PDE3B 3879/4885 |
| US-20240182452-A1 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | PDE3A, PDE3B, PDE5A | SMN1; SMN2 3303/4885AXL 4571/4885PDE3B 2/4885 |
| US-20130048505-A1 | PLATING BATH AND METHOD | EPHX1, CYP7B1, AOC3 | SMN1; SMN2 1955/4885AXL 4463/4885PDE3B 843/4885 |
| US-20250115573-A1 | PYRIDAZINE-BASED PYRIDINE DERIVATIVES AS BIOLOGICALLY ACTIVE AGENTS | HRH4, HRH3, CBR3 | SMN1; SMN2 2953/4885AXL 2899/4885PDE3B 456/4885 |
| US-11897867-B2 | 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer | PDE3B, PDE3A, PDE5A | SMN1; SMN2 3985/4885AXL 4594/4885PDE3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.